Airway Inflammation News and Research

RSS

Silica and dust mites combine to worsen asthma inflammation

Inflammation associated with asthma and other allergic airway diseases can be significantly worsened by exposure to both house dust mite allergens and crystalline silica, according to a new study published in the journal Allergy.

15 Sep 2026

Tirzepatide vs semaglutide for asthma: the difference was smaller than researchers expected

In a US multicenter electronic health record study, researchers compared tirzepatide with semaglutide in adults with asthma and type 2 diabetes, matching 8,176 patients in each treatment group. Asthma exacerbation risk was similar between treatments, while tirzepatide was associated with a lower likelihood of receiving a short-acting beta-agonist prescription.

14 Sep 2026

New biologic therapy significantly reduces COPD flare-ups in trials

Two international clinical trials led in part by researchers at the University of Pittsburgh School of Medicine found that the investigational biologic therapy tozorakimab significantly reduced chronic obstructive pulmonary disease (COPD) flare-ups among patients already receiving standard treatment for the disease compared to patients only receiving standard treatment.

8 Sep 2026

Overuse of short-acting bronchodilator linked to increased risk of cardiovascular diseases and death

Overuse of reliever inhalers is associated with higher risks of developing and dying from cardiovascular disease, including heart failure, heart attack and ischemic stroke, in asthma and COPD patients, according to a study published today in ERJ Open Research.

27 Aug 2026

Superstorm Sandy reshaped indoor fungal communities, with an unexpected asthma result

and lower fungal diversity than non-damaged homes. Despite these persistent but variable fungal changes, researchers found no statistically significant increase in asthma morbidity, impaired lung function, or airway inflammation among children with relatively mild asthma.

13 Aug 2026

Researchers discover new peptide mechanism to treat allergic asthma

A team from the University of Bonn and the Research Center Borstel, Leibniz Lung Center (FZB) has discovered a previously unknown mechanism of action for a synthetic peptide that mitigates excessive inflammatory responses in allergic asthma.

21 Jul 2026

Asthma care is evolving. How FeNO testing is changing the way we treat asthma

Bedfont® Scientific Limited, an innovative leader in breath analysis and Fractional exhaled Nitric Oxide (FeNO) testing for asthma care with the NObreath®, welcomes the news that over 1 million people with asthma are now using combination inhalers following the joint 2024 asthma guidelines from the National Institute for Care Excellence (NICE), the British Thoracic Society (BTS), and the Scottish Intercollegiate Guidelines Network (SIGN).

From NObreath 8 Jul 2026

Engineered immune cells suppress asthma symptoms in allergic mice

Genetically engineered CAR T cells expressing artificial receptor proteins are increasingly used in the clinic to boost the immune system's response against leukemias and other cancers.

6 Jul 2026

Gut fungi play key role in pediatric allergic diseases development

Two new studies jointly published in Nature: The Clinical Microbiome reveal that certain species of fungi in the gut play a key role in the development of immune dysregulation and some pediatric allergic diseases - and may be promising targets for new therapies.

23 Jun 2026

No link between cat ownership and asthma flare-ups in children

A study of over 30,000 children reveals no link between cat exposure and asthma outcomes, challenging previous concerns about pet ownership and asthma control.

12 Jun 2026

Bedfont® Scientific targets international growth at EAACI Congress 2026

Bedfont® Scientific Ltd., an innovative leader in the medical breath analysis industry with almost 50 years of experience, is pleased to join thousands of healthcare experts at this year’s European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026 at stand I03 to showcase its NObreath® and Gastrolyzer® range of non-invasive breath analysis devices.

From NObreath 20 May 2026

GLP-1 weight loss medications linked to significant drop in asthma flares

New research presented at this year's European Congress on Obesity in Istanbul, Turkey (12-15 May) shows the use of the new GLP-1 class of obesity drugs in people with asthma is associated with a 26 % fall in the number of asthma exacerbations and a 14% drop in use of asthma inhaler reliever use. The study is by Simon Høj and Dr Kjell Erik Julius Håkansson, Copenhagen University Hospital, Copenhagen, Denmark and colleagues.

15 May 2026

New therapy reprograms immune cells to reduce asthma inflammation

A collaborative effort between researchers at the Henan Academy of Innovations in Medical Science, Zhengzhou University, and Shenzhen University School of Medicine has provided the first proof-of-principle study demonstrating that targeting a receptor on the surface of anti-inflammatory regulatory T cells (Tregs) can restore their function and alleviate asthma in mice.

31 Mar 2026

Study on inhaler overuse highlights urgent need for better objective asthma monitoring

Bedfont® Scientific Limited, an innovative med-tech company specializing in medical breath analysis devices, welcomes the new study at University Hospital Southampton exploring whether enhanced asthma check-ups can reduce inhaler use among children.

From NObreath 11 Mar 2026

Adults' exposure to diverse microbes may worsen allergic conditions

The "hygiene hypothesis" suggests exposure to diverse types of microbes may protect against developing diseases caused by allergens, but a new Cornell University study in mice reveals that adults' exposure to diverse microbes and allergens may in fact worsen certain allergic conditions.

6 Mar 2026

Early RSV infection turns maternal allergy into a powerful driver of childhood asthma

Early-life RSV infection and parental allergy interact to substantially increase childhood asthma risk, supported by population data from more than 1.5 million children and mechanistic mouse experiments. The study shows that viral infection reprograms neonatal immune responses by altering how maternally transferred allergen-specific antibodies are handled, driving long-term allergic airway disease.

8 Dec 2025

Bedfont® Scientific Limited expands global access to FeNO testing in India

Bedfont® Scientific Limited, world leaders in breath analysis, with over 48 years of experience in designing and manufacturing medical breath analysis devices, has collaborated with Rbeck Healtech Private to make Fractional exhaled Nitric Oxide (FeNO) testing more accessible in India.

From NObreath 1 Dec 2025